Viridian Therapeutics, Inc. - VRDN STOCK NEWS

Viridian Therapeutics has received FDA clearance for its Investigational New Drug application for VRDN-001, a monoclonal antibody aimed at treating thyroid eye disease (TED). The company plans to initiate a Phase 1/2 proof of concept trial involving randomized, placebo-controlled cohorts of TED patients, assessing the drug's potential to improve symptoms rapidly. Expected top-line clinical data is anticipated in the second quarter of 2022. CEO Jonathan Violin emphasizes this milestone as the start of a busy year for the company's development pipeline.

Viridian Therapeutics (NASDAQ: VRDN) announced its IND application for VRDN-001, an antibody for Thyroid Eye Disease (TED), with proof of concept data expected in Q2 2022. The second candidate, VRDN-002, is on schedule for IND filing by year-end 2021. Following a successful public offering in September 2021, the company has a strong cash position of $213.8 million, funding operations into 2024. Third-quarter net loss was $14.03 million, up from $5.5 million year-over-year, reflecting increased R&D and G&A expenses.

Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced CEO Jonathan Violin, Ph.D., will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, at 8:50 AM EST. He will also participate in fireside chats at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 AM GMT, and the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 10:55 AM EST. The company's lead program, VRDN-001, targets insulin-like growth factor-1 receptor for treating thyroid eye disease (TED), an autoimmune condition that can lead to vision complications.

Viridian Therapeutics announced the submission of an investigational new drug (IND) application to the FDA for its VRDN-001 program, targeting Thyroid Eye Disease (TED). This milestone aims to initiate a Phase 1/2 clinical trial, with proof of concept data expected in Q2 2022. VRDN-001 is an anti-IGF-1R monoclonal antibody, previously tested in over 100 oncology patients. The company believes this therapy could significantly improve TED symptoms, including proptosis and double vision, addressing a critical need in an underserved patient population.

Viridian Therapeutics (NASDAQ: VRDN) has announced the presentation of two posters featuring preclinical data on its drug candidates, VRDN-001 and VRDN-002, at the 90th Annual Meeting of the American Thyroid Association from September 30 to October 3, 2021. The posters focus on VRDN-002's pharmacokinetic profile and clinical promise as a second-generation IGF-1R antagonist for Thyroid Eye Disease, and the characterization of VRDN-001 as a potent anti-IGF-1R inhibitory antibody. These developments signal ongoing advancements in treatment options for patients with thyroid eye disease.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) has successfully completed an underwritten public offering, raising approximately $97.7 million. The offering included 7,344,543 shares of common stock at $11.00 each and 23,126 shares of Series B Preferred stock priced at $733.37 each, convertible into about 1,541,810 shares of common stock. Proceeds will fund the advancement of its VRDN-001 and VRDN-002 programs and preclinical developments of VRDN-004 and VRDN-005, alongside general corporate purposes. Jefferies, SVB Leerink, and Evercore ISI were the lead managers for this offering.

Viridian Therapeutics (NASDAQ: VRDN) has priced an underwritten public offering for gross proceeds of approximately $85.0 million. The offering consists of 6,185,454 shares of common stock priced at $11.00 per share and 23,126 shares of series B preferred stock at $733.37 per share, convertible into approximately 1,541,810 shares of common stock. Proceeds will be used for the development of VRDN-001, VRDN-002, VRDN-004, and VRDN-005 programs, as well as general corporate purposes. The offering is expected to close on or about September 23, 2021.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a public offering of its common stock and Series B preferred stock. The offering includes a 30-day option for underwriters to purchase additional common shares. Proceeds will support the advancement of VRDN-001 and VRDN-002 programs, along with preclinical development of VRDN-004 and VRDN-005, in addition to general working capital. Jefferies, SVB Leerink, and Evercore ISI are managing the offering. Regulatory filings are underway, emphasizing that this does not constitute an offer to sell these securities.

Viridian Therapeutics (VRDN) announced a successful pre-IND meeting with the FDA for its lead candidate, VRDN-001, targeting Thyroid Eye Disease (TED). The IND filing is expected in Q4 2021, with Phase 1/2 clinical data anticipated in Q2 2022. The company reported $109 million in cash and equivalents as of June 30, 2021, allowing operations to continue into 2024. R&D expenses rose to $12.6 million due to advancements in lead programs, while net loss increased to $18 million.